sec filing
NASDAQ · BCTX
BriaCell Therapeutics Corp.
Healthcare · Biotechnology
$3.56
Up+$0.66 (+18.54%)
Updated Sep 17, 2026, 9:03 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 19.5M
- P/E ratio
- -1.99
- Dividend yield
- 0.00%
- 52-week range
- $2.60 – $4.66
- Volume
- 66.37K
- Avg. volume
- 71.57K
Price performance
BCTX price history
1M range · 20 trading sessions · Daily adjusted prices
BCTX closed at $3.56 after 20 trading sessions, down 10.10% for the selected period.
- Last close
- $3.56
- Period change
- -10.10%
- Period low
- $3.46
- Period high
- $4.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.57 | $3.62 | $3.52 | $3.56 | 66.37K |
| Sep 15, 2026 | $3.57 | $3.58 | $3.48 | $3.58 | 68.79K |
| Sep 14, 2026 | $3.58 | $3.65 | $3.56 | $3.56 | 96.22K |
| Sep 11, 2026 | $3.68 | $3.769 | $3.61 | $3.63 | 74.71K |
| Sep 10, 2026 | $3.58 | $3.65 | $3.58 | $3.60 | 39.41K |
| Sep 9, 2026 | $3.62 | $3.75 | $3.5501 | $3.63 | 126.31K |
| Sep 8, 2026 | $3.57 | $3.62 | $3.42 | $3.575 | 145.17K |
| Sep 4, 2026 | $3.48 | $3.60 | $3.46 | $3.57 | 108.26K |
| Sep 3, 2026 | $3.62 | $3.6305 | $3.49 | $3.53 | 67.75K |
| Sep 2, 2026 | $3.58 | $3.76 | $3.57 | $3.57 | 95.41K |
| Sep 1, 2026 | $3.625 | $3.65 | $3.4986 | $3.63 | 109.45K |
| Aug 31, 2026 | $3.72 | $3.80 | $3.47 | $3.59 | 260.69K |
| Aug 28, 2026 | $3.71 | $3.76 | $3.6046 | $3.73 | 234.94K |
| Aug 27, 2026 | $3.93 | $3.9526 | $3.60 | $3.71 | 395.22K |
| Aug 26, 2026 | $3.65 | $4.08 | $3.6445 | $4.03 | 281.15K |
| Aug 25, 2026 | $3.61 | $4.10 | $3.55 | $3.77 | 671.14K |
| Aug 24, 2026 | $4.045 | $4.05 | $3.45 | $3.46 | 8.72M |
| Aug 21, 2026 | $3.99 | $4.18 | $3.965 | $4.07 | 150.44K |
| Aug 20, 2026 | $3.97 | $4.18 | $3.90 | $3.93 | 255.84K |
| Aug 19, 2026 | $3.56 | $4.015 | $3.56 | $3.96 | 319.88K |
Latest BCTX news
The latest Smart Investors Daily articles mentioning BCTX.
Stock researchMarket Activity · Short Interest
Loading stock research…